RNA Forex Aktualności
Avidity Biosciences Inks Global Licensing And Research Collaboration Deal With Bristol Myers Squibb
Biopharmaceutical company Avidity Biosciences, Inc. (RNA) announced Tuesday a global licensing and research collaboration with Bristol Myers Squibb (BMY) focused on the discovery, development and commercialization of multiple cardiovascular targets with potential cumulative payments of up to $2.3 billion.
RTTNews
|
346 dni temu
